anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To provide a peroral anti-inflammatory agent containing hyaluronic acid as an active component, having little side effect and high safety and useful for the treatment of inflammation of mucous membrane in amygdalitis, pharyngitis and larynxitis. CONSTITUTION:Hyaluronic acid is used as an active component. The agent can be prepared in various forms such as jelly, a drop-like aqueous agent or a saliva-soluble capsule. Hyaluronic acid is a kind of acidic mucopolysaccharides and widely present between the tissues and in the body fluid of vertebrate animal. Hyaluronic acid can be bonded to the inflammation part of the mucous membrane from the oral cavity to the upper respiratory tract and cure the inflammation by oral administration of hyaluronic acid. In a connective tissue component in a wound healing stage, hyaluronic acid is developed first and, according to the elimination of the acid, chondroitin sulfate is developed to synthesize a collagen, form cicatrices and heal the wound. Early recovery is possible because of the adhesion of hyaluronic acid to the inflammatory mucous membrane, the promotion of exudation of healing substance and the protection of the inflammatory mucous membrane.
The present invention relates to novel mammalian DNA-R proteins and genes that encode such proteins. The invention is directed toward the isolation and characterization of mammalian DNA-R proteins. The invention specifically provides isolated complementary DNA copies of mRNA corresponding to rat and human homologues of a mammalian DNA-R gene. Also provided are recombinant expression constructs capable of expressing the mammalian DNA-R genes of the invention in cultures of transformed prokaryotic and eukaryotic cells, as well as such cultures of transformed cells that synthesise the mammalian catecholamine receptor proteins encoded therein. The invention also provides methods for screening compounds(invitro) that are capable of binding to the mammalian DNA-R prote ins of the invention, and further characterizing the binding properties of such compounds in comparison with known DNA-R agonists and antagonists. Improved methods of pharmacological screening are provided thereby.
In the shoulder pain points, choose 2 to 3 of them for each treatment, apply the coupling agent, which is convenient for the treatment head to stick to the skin, and complete the longitudinal treatment and horizontal treatment. The setting frequency was 4 \~ 8 Hz, the length of the probe was 15 mm, and the pressure was set at 1.5 mJ/mm2. The frequency of each treatment point reached 2 000 \~ 2 500 times, and the hand-held pressure was set to medium-high level. A total of 6 treatments were completed. For patients with unclear pain points or regional pain, the treatment point should be supraspinatus tendon or infraspinatus tendon, and the treatment should be completed with the most severe pain site.
Invasive lobular carcinoma exhibits unique morphological features frequently associated with alterations in CDH1. Although some studies have identified abnormalities in adhesion factors other than E-cadherin, the molecular mechanisms underlying E-cadherin abnormalities in CDH1-unaltered invasive lobular carcinoma remain poorly understood. In this study, we investigated the molecular underpinnings of E-cadherin dysregulation in invasive lobular carcinoma in the absence of CDH1 gene alterations, using comprehensive bioinformatic analyses. We conducted a comparative study of CDH1-mutated and non-mutated invasive lobular carcinoma and evaluated the differences in mRNA levels, reverse-phase protein array, methylation, and miRNAs. We observed that invasive lobular carcinoma cases without CDH1 alterations exhibited a significantly higher incidence of the Claudin-low subtype (p < 0.01). The results of the reverse-phase protein array indicate no significant difference in E-cadherin expression between CDH1-mutated and non-mutated cases. Therefore, abnormalities in E-cadherin production also exist in CDH1 non-mutated invasive lobular carcinoma. Considering that there are no differences in mRNA levels and methylation status, post-translational modifications are the most plausible explanation for the same. Hence, future studies should focus on elucidating the mechanism underlying E-cadherin inactivation via post-translational modifications in CDH1 non-mutated invasive lobular carcinoma.
The invention relates to the technical field of medicine and discloses a preparation method of a phenylpropanoid compound. The invention particularly relates to a method for separating a phenylpropanoid compound from dried root of flemingia macrophylla, and the phenylpropanoid compound is prepared by steps of solvent extraction, column chromatography separation and preparation of liquid-phase separation for purification. The phenylpropanoid compound obtained by the method disclosed by the invention is reported for the first time and has high purity. Proven by experiments, the obtained new phenylpropanoid compound has an effects on inhibiting the content of cell inflammatory factor NO, inhibiting expression of cell inflammatory factors IL-1 beta and IL-6 and inhibiting hydroxyl free radical (-OH), thereby having anti-inflammatory and oxidation resisting activities and benefiting treatment of cervicitis, endometritis, pelvic inflammation, mastitis, faucitis and/or arthritis and various inflammatory diseases. The phenylpropanoid compound can be developed into a new drug. The structural formula of the phenylpropanoid compound disclosed by the invention is as shown in formula (I) in the specification.
This study is an open-label, single-center, randomized, comparative phase IV clinical trial. The purpose of this study is to evaluate the safety and immunogenicity of concomitant administration of EV71 vaccine manufactured by Sinovac (Beijing) Vaccine Technology Co., Ltd. with recombinant hepatitis B vaccine/Group A meningococcal polysaccharide vaccine. 780 healthy infants of 6 months old as participants are randomly assigned into three experimental groups in the ratio 1:1:1. The group I receive EV71 Vaccine (first dose)\& recombinant hepatitis B vaccine on day 0 and EV71 vaccine (second dose)\& Group A meningococcal polysaccharide vaccine on day 30. The group II receive recombinant hepatitis B vaccine on day 0 and Group A meningococcal polysaccharide vaccine on day 30. The group III receive the first and second dose of EV71 Vaccine on day 0 and day 30 respectively.
OctaplasLG® is an industrial donor plasma product pooled from 630 -1520 single donor units. It possesses unique features when compared to standard FFP, such as having a standardized concentration of natural pro- and anti-coagulation factors, a standardized volume as well as being pathogen-free.12 Most importantly, the manufacturing method of OctaplasLG® removes immune complexes and cells in several steps of microfiltration. The manufacturing process also inactivates viral, bacterial and prion pathogen by immune neutralization, solvent-detergent treatment and a prion specific ligand affinity chromatography step.
N-lower alkyl neoalkanamides (N-lower alkyl trialkylacetamides of certain types) of 1 to 4 carbon atoms in the lower alkyl thereof and of 5 to 14 carbon atoms in the neoalkanoyl (or trialkylacetyl) group, e.g., N-methyl- and N-ethyl neodecanamides and N-methyl and N-ethyl neotridecanamides, are new compounds, secondary amides which have insect repellent properties, being especially effective against cockroaches, e.g., the German cockroach. However, they are also useful as repellents for other insects, including American cockroaches, mosquitoes, flies, fleas, ants, and lice. Additionally, they may repel arachnids, such as spiders, ticks and mites. The new neoalkanamides may be synthesized easily, as by reacting a primary lower alkyl amine with a neoalkanoyl halide, e.g. by reacting methyl amine or ethyl amine with neodecanoyl chloride. The most effective of the described amides for insect repellency are normally liquid and are sufficiently volatile to be detectable in air by insects. They may be applied directly to surfaces to be treated or they may be incorporated in detergent compositions, such as built laundry detergents, floor and wall cleaners, rug cleaners and shampoos, hair shampoos, and liquid and bar soaps, and have been found to be sufficiently substantive to the substrate being washed so as to impart insect repelling properties to it.
Approximately 180 study subjects with SIBO identified by positive glucose hydrogen breath (GHB) testing who meet inclusive and exclusive criteria will be randomized to receive either ciprofloxacin 500mg by mouth twice daily, metronidazole 500mg by mouth twice daily, or placebo by mouth twice daily. Subjects will complete a baseline symptom questionnaire and be treated for 14 days. Response will be assessed at end of treatment. The Gastrointestinal Symptom Rating Scale (GSRS) and GHB testing will be performed at the end of treatment. Subjects with a negative GHB at the end of treatment are considered as cured, or treatment success. Patients with treatment success will be reassessed for long-term response to treatment or disease recurrence at 30 days, 4 months, and 9 months using GHB. Symptoms will also be re-assessed at the 30 day, 4 month, and 9 month intervals with GSRS-IBS symptom questionnaire done prior to GHB testing.
Abnormal uterine bleeding (AUB) is the most common and frequent presenting complaint in Gynaecology in all age group especially in perimenopausal and postmenopausal women. The spectrum of AUB in women of our country includes a wide varieties of organic pathology. The objective of this study was to assess the role of endometrial thickness as a predictor of endometrial malignancy among the women presenting with AUB. This cross-sectional descriptive type of observational study was conducted among 122 women of perimenopausal (40-50 years) and 87 women of postmenopausal (>50 years) age group presenting with AUB in the Obstetrics and Gynaecology department of Mymensingh Medical College Hospital, Bangladesh from February 2020 to August 2021. These patients were subjected to a detailed history and meticulous general, systemic and local examination. The relevant investigations like Transvaginal Sonography (TVS) followed by endometrial biopsy by dilatation and curettage were done in all study participants. Most of the women were in the age group 41-45 years in perimenopause and 51-55 years in postmenopause. Mean±SD was 45.8±4.1 years in perimenopause and 56.3±6.4 years in postmenopause. There was statistical significance in developing endometrial malignancy regarding risk factors of nulliparity, Hypertention (HTN), Diabetes mellitus (DM) and hormone intake between perimenopause and postmenopause. Endometrial thickness was measured in perimenopause and postmenopause. Mean±SD of Endometrial thickness (ET) in perimenopause and postmenopause was 11.3±4.4mm and 7.2±6.3mm with statistical significance (p<0.001). Sensitivity, specificity, Positive predictive value (PPV), Negative predictive value (NPV) and accuracy of TVS were 85.5%, 67.4%, 81.2%, 73.8% and 78.7% in perimenopause and 85.9%, 20%, 89%, 75% & 83.9% in postmenopause. Cut off limit of ET in detection of endometrial malignancy was 18.5mm with sensitivity 74.8% and specificity 63.6% in perimenopause and 12.2mm with sensitivity 81.0% and specificity 65.8% in postmenopausal women. Women with AUB, endometrial malignancy should be suspected when endometrial thickness on TVS >18.5mm and >12.2mm in perimenopause and postmenopausal age group respectively. TVS has high sensitivity in detection of endometrial malignancy both in perimenopausal and postmenopausal women with AUB and TVS is a reliable, noninvasive method.
The risk that COVID-19 poses for mortality risk in individuals with schizophrenia in low- and middle-income countries has only been the subject of a few studies. In this retrospective study, we examined the standardized mortality ratio (SMR), by age group and sex, in a cohort of patients diagnosed with schizophrenia (n = 20,417), with second-generation antipsychotics, in a South Brazilian State database (Paraná-Brazil). We performed a linkage with the Brazilian Mortality Information System database between 2020 and 2021. We also assessed in a logistic regression how clozapine could affect COVID-19 mortality controlling by sex, age, and presence of obesity. A secondary analysis was to compare mortality with SMR due to COVID-19 in individuals with and without obesity. Compared to the State population (8,850,682 individuals), those with schizophrenia had more than two times greater risk of dying from COVID-19 (SMR = 2.21, 95 % CI: 1.90-2.55). Between the ages of 16 and 29, their risk is more than ten times higher than the state population (SMR = 10.18, 95 % CI: 4.73-19.33). Obesity showed an almost twofold risk of dying from COVID-19 in the patient's group (OR = 1.89, 95 % CI: 1.39-2.57). Clozapine was not found as a protector or a risk factor for COVID-19 mortality. In Brazil, a middle-income nation, people with schizophrenia are more likely to die prematurely from COVID-19. The burden of schizophrenia is higher in younger and in patients with obesity.
It is intended to provide a method whereby a microparticle dispersion can be highly efficiently produced within a short period of time while preventing drug decomposition, etc. and an apparatus therefor. In the dissolution step, a hardly soluble drug and a dispersion stabilizer are dissolved in a volatile organic solvent in a container (13). In the fixation step following the dissolution step, the organic solvent contained in the solution is evaporated off and a pellet-like residue (1) is obtained as the results of the removal of the organic solvent. This residue (1) is fixed to the inner wall of the container (13). In the water-injection step following the fixation step, water (2) is injected into the container (13). In the irradiation step following the water-injection step, the residue (1) having been fixed to the inner wall of the container (13) is irradiated with laser beams (L) emitted from a laser beam source (11). Thus, the residue (1) is ground into microparticles and then these microparticles are dispersed in the water (2) to give a microparticle dispersion. These microparticles contain the hardly soluble drug and the dispersion stabilizer.
Prepn. of benzoxazolinone derivs. of formula (I) (where R1 and R2 are H or lower alkyl A is a primary, sec. or tert. amino radical and B is a carbonyl or hydroxymethylene radical) comprises reaction of an amine, AH with a cpd. of formula (II) (where Hal is halo). (I) have analgesic and antihypertensive properties.
XELODA can cause fetal harm when administered to a pregnant woman. Capecitabine at doses of 198 mg/kg/day during organogenesis caused malformations and embryo death in mice. In separate pharmacokinetic studies, this dose in mice produced 5'-DFUR AUC values about 0.2 times the corresponding values in patients administered the recommended daily dose. Malformations in mice included cleft palate, anophthalmia, microphthalmia, oligodactyly, polydactyly, syndactyly, kinky tail and dilation of cerebral ventricles. At doses of 90 mg/kg/day, capecitabine given to pregnant monkeys during organogenesis caused fetal death. This dose produced 5'-DFUR AUC values about 0.6 times the corresponding values in patients administered the recommended daily dose.

There are no adequate and well controlled studies of XELODA in pregnant women. If this drug is used during pregnancy, or if a patient becomes pregnant while receiving XELODA, the patient should be apprised of the potential hazard to the fetus. Women should be advised to avoid becoming pregnant while receiving treatment with XELODA [see Warnings and Precautions (5.6)].
Introduction: The search for fast and efficient treatment for dermonecrotic lesions caused by the venom of the spider from the Loxosceles simillis, is a demand in health. Prednisolone is one of the most used drugs, however it has side effects. In this context, addictionally gold nanoparticles (GNPs) have anti-inflammatory, antioxidant, and antibacterial properties. The use of photobiomodulation has show to be efficient in the process of tissue repair. Therefore, the purpose of this study was to investigate the anti-inflammatory effect of photobiomodulation and GNPs associated or not with a low concentration of prednisolone in animal models of dermonecrotic lesion.Methodology: For this, rabbits with venon-induced dermonecrotic lesion were subjected to topical treatment with prednisolone + laser or GNPs + laser or Pred-GNPs + laser. The area of edema, necrosis and erythema were measured. On the last day of treatment, the animals were euthanized to remove the organs for histopathological and biochemical analysis.Results: All treatments combinations were effective in promoting the reduction of necrotic tissue and erythema.Conclusion: With this results, we suggest that the use of laser and nanoparticles, associated or not with prednisolone, should be considered for the treatment of dermonecrotic injury.
OBJECTIVE: Here we trained an automatic phenotype assessment tool to recognize syndromic ears in two syndromes in fetuses-=CHARGE and Mandibulo-Facial Dysostosis Guion Almeida type (MFDGA)-versus controls.
METHOD: We trained an automatic model on all profile pictures of children diagnosed with genetically confirmed MFDGA and CHARGE syndromes, and a cohort of control patients, collected from 1981 to 2023 in Necker Hospital (Paris) with a visible external ear. The model consisted in extracting landmarks from photographs of external ears, in applying geometric morphometry methods, and in a classification step using machine learning. The approach was then tested on photographs of two groups of fetuses: controls and fetuses with CHARGE and MFDGA syndromes.
RESULTS: The training set contained a total of 1489 ear photographs from 526 children. The validation set contained a total of 51 ear photographs from 51 fetuses. The overall accuracy was 72.6% (58.3%-84.1%, p < 0.001), and 76.4%, 74.9%, and 86.2% respectively for CHARGE, control and MFDGA fetuses. The area under the curves were 86.8%, 87.5%, and 90.3% respectively for CHARGE, controls, and MFDGA fetuses.
CONCLUSION: We report the first automatic fetal ear phenotyping model, with satisfactory classification performances. Further validations are required before using this approach as a diagnostic tool.
PURPOSE: A method for extracting polysaccharide from sea algae is provided to extract polysaccharide at high yield and to use as a material for foods, medicines, and cosmetics. CONSTITUTION: A polysaccharide is isolated from sea algae by radiation irradiation. The sea algae are green, brown, or red algae. The polysaccharide is alginic acid, fucoidan, carrageenan, porphyran, or laminarin. The radiation is gamma ray or electronic beam. The polysaccharide is obtained from sea algae using organic solvent such as ethanol, calcium chloride, or hydrochloric acid, or hot water. The polysaccharide is used for sitological, pharmaceutical, or cosmetic composition.
Based on randomization (n= 314) Potential participants will be vaccinated with TCV on Day 0 and two doses of MR vaccine will be given on Day 0 and Day 180 . A blood sample (2-3 ml) will be collected for immunological assay on Day 0, Day 28 and Day 208 . All details will be recorded in the eCRF.
Decreased levels of hyaluronic acid (HA) are found in subjects receiving a variety of therapeutic interventions, for example, chemotherapy, to treat pathological conditions. The use of high molecular weight (HMW) HA is described. More particularly described herein is the use of exogenous forms of HWM HA as an adjuvant in the restoration of the local tissue specific stem cell microenvironment to enhance stem cell recovery or engraftment and thus tissue recovery and remodeling following stem cell transplantation or other therapies. The effect of HMW HA on hematopoietic stem cells is illustrative of the invention. Mice having severe bone marrow hypoplasia and pancytopenia resulting from treatment with 5-fluorouracil recovered more rapidly if treated wit HMW HA. Similarly, mice transplanted with hematopoietic stem cells following lethal irradiation exhibited enhanced recovery of peripheral blood cell counts when treated with HMW HA as an adjuvant therapy compared to control mice transplanted with hematopoietic stem cells without adjuvant therapy.
Each year, more than 40 million Americans present to US emergency departments (EDs) for evaluation after traumatic stress exposure. The overwhelming majority of these individuals are discharged to home after evaluation. A wealth of data demonstrates that the development of adverse posttraumatic neuropsychiatric sequelae such as posttraumatic stress disorder (PTSD) are common in this population, and that individuals with a past history of traumatic stress exposure and/or posttraumatic stress symptoms, such as military veterans, are at increased risk. Unfortunately, no secondary preventive interventions are currently widely available that can prevent PTSD among those at high risk. This pilot Written Exposure Therapy to Improve Lives after Stress Exposure (WISE) trial will assess the ability of written exposure therapy to reduce the incidence and severity of PTSD after one of the most common traumatic stress exposures in industrialized countries, motor vehicle collision (MVC). Written exposure therapy is an evidence-based, low-cost intervention that has been demonstrated to be efficacious in treating chronic PTSD symptoms after a variety of traumatic stress exposures, including MVC. However, WISE has never been tested as a secondary preventive intervention. In addition, the efficacy of written exposure therapy when administered as a telehealth intervention has never been assessed, despite the fact that almost a quarter of US veterans live in rural communities that have greater barriers to obtaining in-person care. This WISE pilot trial will randomize 40 individuals who present to a study ED for care after MVC to five sessions of written exposure therapy vs. unemotional writing control. Both exposure and control interventions will be administered via telehealth (n=40), with 20 individuals receiving written exposure therapy and 20 receiving unemotional writing intervention. The same therapists will administer both interventions. Participants will be assessed via traditional self-report surveys. Results of this trial will demonstrate the feasibility and potential efficacy of WISE to reduce the development of PTSD after traumatic stress exposure and will provide the data necessary to design/support a large-scale trial.
The present invention discloses a yang strengthening and cold dispersing solid mutton soup and belongs to the field of health-care food. The solid mutton soup contains the following raw materials: sheep bones, sheep lean meat, ginsengs, donkey-hide gelatin, radix paeoniaerubra, ramulus cinnamomi, Chinese wolfberry fruits, cornua cervi pantotrichum, cortex eucommiae and fructus psoraleae. The solid mutton soup has good health-care efficacies of nourishing yin and strengthening yang, supplementing kidney and strengthening bones, and warming middle warmer and dispelling cold, and is suitable for the consumption of patients with deficiency-cold, wet cold and premature ejaculation. The health-care food is prominent in health-care effects and adjuvant therapeutic effects, delicious in taste, free of toxic side effects, and suitable for a long-term consumption for warming and supplementing. The mutton soup is made into solid powder, convenient for consumption, and simple and easy in production process. The mutton soup raw materials are sufficient and low in cost, and the mutton soup is easy for production conversion to create greater social value.